ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

142
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
Refresh
12 Jan 2017 14:54

IPO Pipeline to Remain Strong as PE Funds, Quasi-Govt Promoters Aim for Portfolio Exits

Primary issuances are expected to remain strong in 2017 following a five-year high in funds raised in 2016 (Rs 220bn) even as Fed rate expectations...

Logo
1.3k Views
Share
31 Dec 2016 20:34Syndicated

Pakistan Market Outlook 2017

Pakistan market is expected to continue its uptrend in 2017 given tangible gains from China Pakistan Economic Corridor (CPEC) projects and rising...

Logo
379 Views
Share
bearishMylan NV
15 Dec 2016 21:35

Indictments Starting to Appear

The US Department of Justice (DOJ) filed charges (attached) against two former senior executives of Heritage Pharmaceuticals, a subsidiary of Pune,...

Share
13 Dec 2016 11:44

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

08 Dec 2016 08:24

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...

Share
x